Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

494 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
Michiwaki Y, Hata N, Mizoguchi M, Hiwatashi A, Kuga D, Hatae R, Akagi Y, Amemiya T, Fujioka Y, Togao O, Suzuki SO, Yoshimoto K, Iwaki T, Iihara K. Michiwaki Y, et al. Among authors: mizoguchi m. Clin Neurol Neurosurg. 2019 Dec;187:105556. doi: 10.1016/j.clineuro.2019.105556. Epub 2019 Oct 12. Clin Neurol Neurosurg. 2019. PMID: 31639630 Free article.
Loss of heterozygosity analysis in malignant gliomas.
Mizoguchi M, Kuga D, Guan Y, Hata N, Nakamizo A, Yoshimoto K, Sasaki T. Mizoguchi M, et al. Brain Tumor Pathol. 2011 Jul;28(3):191-6. doi: 10.1007/s10014-011-0038-0. Epub 2011 Jun 1. Brain Tumor Pathol. 2011. PMID: 21629980 Review.
Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
Yoshimoto K, Hatae R, Sangatsuda Y, Suzuki SO, Hata N, Akagi Y, Kuga D, Hideki M, Yamashita K, Togao O, Hiwatashi A, Iwaki T, Mizoguchi M, Iihara K. Yoshimoto K, et al. Among authors: mizoguchi m. Brain Tumor Pathol. 2017 Jul;34(3):103-112. doi: 10.1007/s10014-017-0287-7. Epub 2017 Apr 26. Brain Tumor Pathol. 2017. PMID: 28447171
First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Hata N, Mizoguchi M, Kuga D, Hatae R, Akagi Y, Sangatsuda Y, Amemiya T, Michiwaki Y, Fujioka Y, Takigawa K, Suzuki SO, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iihara K. Hata N, et al. Among authors: mizoguchi m. J Neurooncol. 2020 Feb;146(3):451-458. doi: 10.1007/s11060-019-03339-0. Epub 2020 Feb 4. J Neurooncol. 2020. PMID: 32020475
Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
Fujioka Y, Hata N, Akagi Y, Kuga D, Hatae R, Sangatsuda Y, Michiwaki Y, Amemiya T, Takigawa K, Funakoshi Y, Sako A, Iwaki T, Iihara K, Mizoguchi M. Fujioka Y, et al. Among authors: mizoguchi m. J Neurooncol. 2021 Mar;152(1):47-54. doi: 10.1007/s11060-020-03682-7. Epub 2021 Jan 8. J Neurooncol. 2021. PMID: 33417137 Free PMC article.
Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study.
Funakoshi Y, Takigawa K, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Otsuji R, Sako A, Yoshitake T, Togao O, Hiwatashi A, Iwaki T, Mizoguchi M, Yoshimoto K. Funakoshi Y, et al. Among authors: mizoguchi m. World Neurosurg. 2022 Mar;159:e479-e487. doi: 10.1016/j.wneu.2021.12.075. Epub 2021 Dec 25. World Neurosurg. 2022. PMID: 34958993
494 results